Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  Cure Hepatitis C in 8 Weeks: Maviret, the Hepatitis C Drug with the Best Efficacy in the World, has Entered China

Cure Hepatitis C in 8 Weeks: Maviret, the Hepatitis C Drug with the Best Efficacy in the World, has Entered China

June 04, 2019 By 1℃

The National Medical Products Administration of China (NMPA) has approved the marketing of AbbVie’s direct-acting antiviral (DAA) Maviret (glecaprevir/pibrentasvir) on May 15, 2019. The hepatitis C drug with the best efficacy in the world has thus entered China, which is used to treat adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. With the advantage of curing hepatitis C in 8 weeks, Maviret was included in the second batch of clinically imperative overseas new drugs released by the NMPA upon “therapeutic advantages over marketed products”.

The global hepatitis C drug market continues to shrink due to the unprecedentedly good clinical efficacy of DAAs. However, upon the advantage of curing hepatitis C in 8 weeks, Maviret has achieved stunning performance since marketed and feels like a hepatitis C terminator. The first DAA was not approved for marketing in China until Apr. 2017, however, there have been so far 10 DAAs that have entered China, and AbbVie’s Maviret just approved has attracted even more attention!

The clinical trial data of Maviret, the performance of some products in the global hepatitis C drug market, and marketing situation of DAAs in China will be introduced below!

I. Curing hepatitis C in 8 weeks: Maviret, the hepatitis C drug with the best efficacy

Maviret (glecaprevir/pibrentasvir) was approved in the U.S. in July 2017, and its sales in 2018 already made it rank among global top 50 pharmaceutical products by sales.

Prescribing Information

According to the clinical trial data of Maviret, the SVR12 rate in patients with all major HCV genotypes (genotype 1-6), who were previously untreated and without cirrhosis, reached up to 99%, and the treatment course could be shortened to 8 weeks. This therapeutic regimen does not require the combination with ribavirin and is taken once daily. Maviret is applicable to patients with any degree of renal function damage (including those who underwent dialysis) without the need to adjust the dosage of administration because it is not metabolized via kidney, and its SVR12 rate approaches 100%, with good safety.

II. Global hepatitis C drug market: from sofosbuvir to Maviret

Gilead launched sofosbuvir, the first generation, in 2013, to start a new era of the global hepatitis C DAAs. Since then, Gilead, J & J, AbbVie, BMS, and MSD have successively launched many DAAs.

Gilead’s Sovaldi, Harvoni, and Epclusa, and AbbVie’s Mavyret have been the most successful among the DAAs, wherein, Harvoni’s sales peaked at USD13.864 billion!

However, the global hepatitis C drug market has rapidly shrunk owing to the hepatitis C disease’s particularity. Mavyret has outshone amid the big decline of the HCV drug market, which was marketed in 2017, with a shorter treatment cycle (the only DAA with a treatment course of 8 weeks) and largely reduced treatment expenses. Its sales performance has skyrocketed since marketed!

Therefore, the global hepatitis C drug market began with sofosbuvir and will be terminated by Maviret!

III. China following closely to enter the era of hepatitis C cure

China will enter the era of hepatitis C cure by following closely the EU and U.S. There have been 8 DAAs regimens approved in China, and 3 DAAs in the marketing review stage; all of them are expected to be approved for marketing in 2019.

According to the prices released by the enterprises so far:

1. Prices of imported drugs are between RMB58,000-60,000/12 weeks

2. Prices of Chinese-produced drugs are about RMB40,000/12 weeks

China will enter the new era of complete cure with DAAs + Peg-IFN-α + ribavirin or all-oral DAAs, as DAAs are approved for marketing in China.

DAAs marketed/in the marketing review stage in China

Trade name

Generic name

Therapeutic regimen

China

Company

Daklinza

Daclatasvir

DCV+ASV, 24 weeks

Apr. 24, 2017

BMS

Sunvepra

Asunaprevir

Olysio

Simeprevir

SMV, 24/48 weeks

Aug. 24, 2017

J & J

Viekirax

Ombitasvir / paritaprevir / ritonavir

OBV/PTV+DSV, 12 weeks

Sep. 21, 2017

AbbVie

Exviera

Dasabuvir

Sep. 21, 2017

Sovaldi

Sofosbuvir

SOF+PR, 12 weeks

Sep. 21, 2017

Gilead Sciences

SOF+RBV, 12/24 weeks

Zepatier

Elbasvir

Grazoprevir

EBR/GRZ, 12 weeks

Apr. 28, 2018

Merck

Epclusa

Sofosbuvir

Velpatasvir

SOF+VEL, 12 weeks

May 30, 2018

Gilead Sciences

Ganovo

Danoprevir

Danoprevir + PR, 12 weeks

June 13, 2018

Ascletis

Maviret

Glecaprevir

Pibrentasvir

GLE+PIB, 8 weeks

May 15, 2019

AbbVie

Harvoni

Ledipasvir

Sofosbuvir

LDV+SOF, 12 weeks

Applied for marketing

Gilead Sciences

 

KW-136

KW-136+SOF

Applied for marketing

Kawin Technology

 

Ravidasvir

Ravidasvir+danoprevir

Applied for marketing

Ascletis

Register as Visitor to CPhI China 2019 NOW!

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com.

 

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat